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Objective To compare the in vitro activity of midecamycin diacetate to that of five other macrolides
(erythromycin, clarithromycin, roxithromycin, azithromycin, and josamycin) and of clindamycin against
146 clinical isolates of Streptococcus pyogenes, with regard to three different phenotypes of erythromycin
resistance.
Methods Susceptibility pattern and resistance phenotype were determined by disk diffusion method and
double disk test. Minimal inhibitory concentrations of antibiotics were obtained by the agar dilution method
and evaluated according to the recommendations of the ‘Comite´ de l’Antibiogramme de la Socie´te´ Franc¸aise
de Microbiologie’ (CA-SFM). The major determinants of erythromycin resistance in S. pyogenes (ermB,
ermTR and mefA genes) were investigated by specific amplification protocols.
Results Most of the isolates of S. pyogenes collected during 1995–99 were susceptible to midecamycin (93.8%),
erythromycin (90.4%), clarithromycin (93.2%), roxithromycin (91.8%), azithromycin (88.4%), josamycin
(94.5%), and clindamycin (94.5%). According to the CA-SFM criteria, 132 of the 146 isolates studied
were susceptible to erythromycin (MICs 1 mg/L), four were intermediate (MICs 2–4 mg/L), and 10 were
resistant (MICs> 4 mg/L). Only nine isolates were midecamycin resistant (MICs> 4 mg/L), and the others
were susceptible. The increased activity of midecamycin (MIC90 0.06 mg/L), as compared to
erythromycin (MIC90¼ 0.5 mg/L) and to other 14- or 15-membered macrolides, was related to the absence
of the ermB determinant in seven isolates which displayed an efflux phenotype (five isolates) or an
inducible resistance phenotype due to an ermTR determinant (two isolates).
Conclusion Midecamycin diacetate is active against most S. pyogenes strains isolated in France and may
represent an attractive alternative to the treatment of streptococcal infections due to resistant isolates
with efflux of erythromycin.
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INTRODUCTION
Streptococcus pyogenes is naturally susceptible to penicillin G,
which remains the main therapeutic agent against streptococcal
infections. However, macrolides, and especially erythromycin,
are used in patients who are allergic to penicillin. The pre-
valence of erythromycin resistance has increased quickly during
the last decade in Finland [1], Italy [2], Sweden [3], Spain [4,5]
and the USA [6]. In France, the emergence of erythromycin
resistance appeared to be more limited, and its prevalence
remained under 10% [7].
This rapid emergence of erythromycin resistance of Strepto-
coccus pyogenes has been related to changes in the antimicrobial
susceptibility pattern and to the clonal spread of strains belong-
ing to a limited number of T and M serotypes [5,8]. In areas of
high prevalence of erythromycin resistance, the previously
observed resistance to macrolides by methylation of 23S rRNA
via ErmB methylase (MLSB phenotype) has been overtaken by a
novel resistance pattern (M phenotype) [9]. The M phenotype
has been characterized by cross-resistance to 14- and 15-
membered macrolides and by preserved susceptibility to 16-
membered macrolides and to lincosamides. A drug-efflux
mechanism of resistance, via the expression of the mef efflux
pump, was further demonstrated in streptococcal strains [10].
Increased and widespread erythromycin resistance is of con-
cern and has compromised the clinical use of erythromycin in
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several countries with a high prevalence of resistant strains,
leading to the development of new molecules with improved
activity. Midecamycin is a 16-membered macrolide that is active
against both erythromycin-susceptible and efflux-mediated
erythromycin-resistant strains. In addition, the diacetate salt
of this molecule (Mosil; Me´narini France SA, Rungis, France)
reduces the gastrointestinal side effects and improves its phar-
macokinetic profile.
The aim of this study was to evaluate the activity of mid-
ecamycin against clinical isolates of Streptococcus pyogenes repre-
sentative of the French streptococcal isolates between 1995 and
1999. The in vitro activity of midecamycin has been analyzed
according to the phenotype and the genotype of resistance of
strains, and has been compared to the activities of five other
macrolides (erythromycin, clarithromycin, roxithromycin,
azithromycin, and josamycin) and of clindamycin.
MATERIALS AND METHODS
Bacterial strains
In total, 146 clinical isolates of Streptococcus pyogenes from blood
(40 isolates), throat swabs (12 isolates) and pus samples (94
isolates) were investigated. The isolates were collected from
different parts of France at the Centre National de Re´fe´rence
des Streptocoques between 1995 and 1999. All isolates were
stored at 80 8C in brain–heart infusion broth supplemented
with 15% glycerol. Subcultures were carried out on Columbia
agar with 5% sheep blood (bioMe´rieux, La-Balme-les-Grottes,
France).
Antibiotics
Erythromycin and clarithromycin (Abbott-France, Rungis,
France), roxithromycin (Roussel-Diamant, Paris, France),
azithromycin dihydrate (Pfizer, Orsay, France), josamycin
(Aventis, Antony, France), midecamycin diacetate (Menarini,
Rungis, France) and clindamycin chlorhydrate (Pharmacia-
Upjohn, Paris-La De´fense, France) were supplied by the
manufacturers as titrated powders. Erythromycin (15 UI) and
clindamycin (2 UI) paper-load disks were from Bio-Rad (Ivry-
sur-Seine, France). Erythromycin and clindamycin E-test
strips were provided by AB-Biodisk (distributed by AES,
Combourg, France).
Antimicrobial susceptibility testing
Erythromycin-resistant strains were initially identified by the
disk diffusion method according to the recommendations of the
‘Comite´ de l’Antibiogramme de la Socie´te´ Franc¸aise de Micro-
biologie’ (CA-SFM) (zone diameter 16 mm for resistant
strains, 17–21 mm for intermediate strains, and 22 mm for
susceptible strains) [11]. Minimal inhibitory concentrations
(MICs) were determined by the agar dilution technique using
Mueller–Hinton agar (bioMe´rieux) supplemented with 5%
sheep blood (Bio-Rad). The plates were inoculated with a
Steers replicator delivering 104 bacteria per spot and incubated
overnight at 35 8C in a 5% CO2 atmosphere. The MIC was
defined as the lowest concentration of antibiotic that comple-
tely inhibited bacterial growth. The MIC breakpoints proposed
for streptococci by the CA-SFM [11] were considered for
erythromycin, clarithromycin, roxithromycin, azithromycin,
josamycin and midecamycin diacetate (susceptible, 1 mg/L;
intermediate, 2–4 mg/L; resistant, >4 mg/L), and for clinda-
mycin (susceptible, 2 mg/L; resistant, >2 mg/L). Enterococcus
faecalis JH2-2, Enterococcus faecalis ATCC 29212T and Staphylo-
coccus aureus ATCC 25923 were used as quality controls for these
experiments.
Phenotypes of resistance to erythromycin were classified on
the basis of a double disk test and E-test strips with both
erythromycin and clindamycin as described by Seppa¨la¨ et al
[1,9]. After 18–42 h of incubation in a CO2-enriched atmo-
sphere, resistance to both erythromycin and clindamycin, with
no blunting zone of inhibition, was considered as constitutive
resistance (CR). Resistance to erythromycin, together with a
blunting of the clindamycin zone of inhibition proximal to the
erythromycin disk, indicated inducible resistance (IR). A small
inhibition zone around the erythromycin disk, together with a
low MIC by E-test strip, and with susceptibility to clindamycin
without any blunting of the zone of inhibition, was regarded as
an efflux (M) phenotype.
PCR assays for erythromycin resistance determinants
Detection of ermB, ermTR and mefA genes was carried out in
isolates of S. pyogenes with erythromycin zone sizes of <22 mm
and also in a random selection of 15 susceptible strains.
For DNA isolation, 5–10 colonies from a fresh bacterial
culture were suspended in 1 mL of phosphate-buffered saline
(PBS) and washed twice. Mutanolysin (1 UI per tube) was
added, and the mixture was incubated at 37 8C for 1 h. After
centrifugation, the bacteria were resuspended in 100mL of PBS.
The crude bacterial lysate was obtained by successive boiling
and freezing steps.
The ermB and mefA genes were detected by PCR by using the
oligonucleotide primer pairs described by Sutcliffe et al [12]
(the expected PCR products were 639 bp and 348 bp, respec-
tively). The ermTR gene was detected with the primers III8 and
III10, designed by Seppa¨la¨ et al [13] (the expected PCR product
was 208 bp). DNA amplification was carried out by using a
Perkin 2400 thermocycler (Perkin-Elmer, Norwalk CT, USA).
The PCR mixture of 25 mL contained 0.2 mM of each de-
oxyribonucleotide, 8 pmol of oligonucleotide primers, 2 mM
MgCl2, 1 U of Taq polymerase, and 5 mL of bacterial lysate.
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The amplification protocol consisted of a 5-min melt at 94 8C,
followed by 35 cycles (1-min melt at 94 8C, 1-min primer
annealing step at 50 8C, and 1-min extension step at 72 8C),
with a final extension step of 10 min at 72 8C.
The PCR amplification product was analyzed by 1% agarose
gel electrophoresis in 1TBE (0.089 M Tris, 0.089 M boric
acid, 0.025 M Na2EDTA, pH 8) buffer. The size of each PCR
product was estimated by using standard molecular weight
markers (ladder 50–2000 bp, Bio-Rad). In each experiment,
the bands obtained for clinical isolates were compared to the
expected PCR product from reference strains carrying ermB
(Streptococcus pyogenes AC1), ermTR (Streptococcus pyogenes
A200), or mefA (Streptococcus pyogenes 02C1064).
RESULTS
Of the 146 isolates of Streptococcus pyogenes, 132 (90.4%) were
categorized as susceptible to erythromycin (MICs 1 mg/L),
including 129 isolates with erythromycin MICs 0.06 mg/L
and three isolates with higher MICs (0.5–1 mg/L) (Table 1).
Four isolates were categorized as intermediate (MICs 2–4 mg/
L) and 10 isolates as resistant (MICs> 4 mg/L).
Table 1 Susceptibility and distribution ofMICs of macrolides and clindamycin for146 isolates of Streptococcus pyogenes
Susceptibility categorizationa Distribution of MICs (mg/L)a
Sb I R 0.06 0.125 0.25 0.5 1 2 4 8 16 32 64 MIC90
Erythromycin 132 4 10 129 2 1 3 1 1 9 0.5
Clarithromycin 136 1 9 132 4 1 9 0.06
Roxithromycin 134 2 10 130 1 3 2 9 0.5
Azithromycin 129 3 14 129 1 2 3 1 1 9 4
Josamycin 138 ^ 8 134 3 1 8 0.06
Midecamycin 137 ^ 9 136 1 1 8 0.06
Clindamycin 138 ^ 8 137 1 4 4 0.06
aNumber of strains.
bS, susceptibility; I, intermediate resistance; R, resistance.
Table2 Minimum inhibitory concentrations of erythromycin, midecamycin and clindamycin, phenotype of erythromycin resistance, and PCR-based genotype
of17 strains of Streptococcus pyogeneswith anMIC of erythromycin greater than 0.06mg/L
Minimum inhibitory concentrations (mg/L)
Strain Erythromycin Midecamycin Clindamycin Phenotypea Resistance determinant
HDP95E959 64 64 32 CR ermB
HDP95E960 64 64 16 CR ermB
HDP95E071 64 64 16 CR ermB
HDP95E051 64 64 16 CR ermB
HDP97172 64 64 32 CR ermBþmef
HDP97132 64 64 32 CR ermB
HDP99074 64 64 32 CR ermB
HDP98178 64 64 0.125 IR ermB
HDP95E358 0.5 16 16 IR ermTR
HDP95E826 2 0.06 0.06 IR ermTR
HDP95E541 0.5 0.06 0.06 IR ermTR
HDP98024 2 0.06 0.06 M mef
HDP96094 8 0.06 0.06 M mef
HDP95E868 2 0.06 0.06 M mef
HDP95E433 1 0.06 0.06 M mef
HDP98047 4 0.06 0.06 M mef
HDP98428 64 0.5 0.06 UC None
aErythromycin resistance phenotype was designed according to the double disk diffusion test with erythromycin and clindamycin disks and E test strips: CR,
constitutive resistance; IR, inducible resistance; M, efflux; UC, unclassified.
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The resistance phenotypes of 17 isolates with erythromycin
MICs greater than 0.06 mg/L are shown in Table 2: seven
isolates (41.2%) appeared to have a CR phenotype. All the
CR isolates were resistant to 64 mg/L erythromycin and
demonstrated cross-resistance to all 14-, 15- and 16-membered
macrolides tested, and to clindamycin. The ermB gene was
detected by PCR assay in all of these CR isolates. In addition
to this ermB methylase gene, a mefA gene was detected in one of
the CR isolates (HDP97172).
The IR phenotype was observed in four of 17 isolates
(23.5%). PCR investigation demonstrated that this phenotype
was associated with the presence of ermB in one isolate, and of
ermTR in three isolates. The high MIC values of midecamycin
and clindamycin for strain HDP95E358 (16 mg/L), as com-
pared to the MIC of erythromycin (0.5 mg/L) (Table 2), suggest
another mechanism of resistance in addition to the expression of
ermTR.
The efflux phenotype (M) observed in five of 17 isolates
(29.4%) was related to the presence of mefA.
None of the erythromycin-susceptible isolates tested for
which the MIC of erythromycin was equal to or less than
0.06 mg/L carried these resistance determinants.
Isolate HDP98428 displayed a particular pattern of resistance:
MICs of erythromycin, azithromycin, midecamycin and clin-
damycin were 64, 64, 0.5 and 0.06 mg/L, respectively.
This pattern was not associated with the detection of an
erythromycin resistance determinant. This unclassified pheno-
type may correspond to a mutation or insertion in L4 ribosomal
protein conferring erythromycin resistance, as demonstrated
for rare strains of pneumococci [14].
Midecamycin and josamycin (MIC90 0.06 mg/L) were at
least six-fold more active than erythromycin, roxithromycin or
azithromycin (MIC90 0.5–4 mg/L) (Table 1). This could be
explained by better efficacy of 16-membered macrolides as
compared to erythromycin against all the efflux erythromy-
cin-resistant isolates and against two inducible resistant isolates
(Table 2). Similarly, the antimicrobial activity of clindamycin
was limited against constitutive erythromycin-resistant isolates
(MICs 16–32 mg/L), but appeared to be preserved against
isolates with inducible resistance (MICs 0.06–16 mg/L) or
efflux determinant (MICs 0.06 mg/L).
DISCUSSION
The prevalence of erythromycin resistance in Streptococcus pyo-
genes is currently low in France. The values observed in this
study (6.8%) are slightly higher than those found in two
previous studies in France. These were 5.2% in the 1995
national survey of Streptococcus pyogenes infections, which
involved 1462 isolates collected, including 122 from blood
cultures [7], and 6.2% in the recent study of 15 000 pharyngeal
isolates from pediatric patients [15]. Greater variations in
erythromycin resistance prevalence have previously been found
in other countries. These changes were related to the clonal
expansion of few resistant strains which belonged to the T12,
T4 or T8,25 serotypes and harbored an efflux determinant
[2,3,8]. In our study, the M phenotype accounted for 29.4% of
the isolates in which resistance to erythromycin was detected.
This proportion was lower than the prevalence reported in
Finland and the USA (30–40%), Italy and Sweden (50%), or
Spain (90–95%) [2,4,5,9].
In our study, the in vitro activity of midecamycin was
similar to that of roxithromycin, clarithromycin, josamycin or
clindamycin against macrolide-susceptible Streptococcus pyogenes.
The efficacy of midecamycin was limited against all constitutive
and a few inducible erythromycin-resistant isolates of Strepto-
coccus pyogenes, as revealed by high MICs. All constitutive
erythromycin-resistant isolates were also resistant to the other
14-, 15- and 16-membered macrolides and to clindamycin
(MICs 64 mg/L). In contrast, among inducible-resistant
strains, two isolates were resistant to 16-membered macrolides
(MICs 16 and 64 mg/L), while two other isolates remained
susceptible (MICs0.06 mg/L). Therefore, the use of mide-
camycin as well as josamycin against the IR strains should be
regarded with caution [16].
The susceptibility to midecamycin, josamycin and clinda-
mycin in efflux resistant Streptococcus pyogenes is of interest, since
all 14- or 15-membered macrolides are of limited value for
therapy of such resistant strains. Against efflux phenotype
strains, the MICs of midecamycin diacetate reported here are
similar to those previously published for miocamycin, one of
its semisynthetic derivatives [4,9], or for josamycin [17].
The present results show that midecamycin diacetate is
promising for the treatment of infections caused by Streptococcus
pyogenes, particularly when the spread of an efflux mechanism of
resistance is suspected. Its therapeutic benefit also clearly appears
when penicillin or erythromycin are contraindicated for allergy
and gastrointestinal disorders, respectively.
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